MAPT and Alzheimer disease: Because STUB1 is a miR-21-5p target, it can be speculated that in AD, augmented miR-21-5p levels can exacerbate the neurodegenerative process by reducing STUB1/CHIP activity, leading to less efficient Tau and β-amyloid clearance (Lee et al., 2018).